Harvard Bioscience, Inc. (HBIO) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts HBIO Hot Sheet
Price: $8.67 --0%
Revenue Growth %: +6.1%
Financial Fact:
Basic earnings per common share: -0.05
Today's EPS Names:
ATS, SICP, FTCO, More
Revenue Growth %: +6.1%
Financial Fact:
Basic earnings per common share: -0.05
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Harvard Bioscience, Inc. (NASDAQ: HBIO) reported Q4 EPS of $0.02, $0.02 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $28.2 million versus the consensus estimate of $29.2 million.
For earnings history and earnings-related data on Harvard Bioscience, Inc. (HBIO) click here.
For earnings history and earnings-related data on Harvard Bioscience, Inc. (HBIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- CPS Technologies (CPSH) Reports In-Line Q3 EPS
- McDonald's posts better-than-expected third-quarter comparable sales
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
